114 related articles for article (PubMed ID: 19538242)
1. Investigation of the effect of oral metformin on dipeptidylpeptidase-4 (DPP-4) activity in Type 2 diabetes.
Cuthbertson J; Patterson S; O'Harte FP; Bell PM
Diabet Med; 2009 Jun; 26(6):649-54. PubMed ID: 19538242
[TBL] [Abstract][Full Text] [Related]
2. Addition of metformin to exogenous glucagon-like peptide-1 results in increased serum glucagon-like peptide-1 concentrations and greater glucose lowering in type 2 diabetes mellitus.
Cuthbertson J; Patterson S; O'Harte FP; Bell PM
Metabolism; 2011 Jan; 60(1):52-6. PubMed ID: 20152998
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of dipeptidyl peptidase IV activity by oral metformin in Type 2 diabetes.
Lindsay JR; Duffy NA; McKillop AM; Ardill J; O'Harte FP; Flatt PR; Bell PM
Diabet Med; 2005 May; 22(5):654-7. PubMed ID: 15842525
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
[TBL] [Abstract][Full Text] [Related]
5. Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes.
Brazg R; Xu L; Dalla Man C; Cobelli C; Thomas K; Stein PP
Diabetes Obes Metab; 2007 Mar; 9(2):186-93. PubMed ID: 17300594
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
[TBL] [Abstract][Full Text] [Related]
7. Effects of chronic treatment with metformin on dipeptidyl peptidase-4 activity, glucagon-like peptide 1 and ghrelin in obese patients with Type 2 diabetes mellitus.
Thondam SK; Cross A; Cuthbertson DJ; Wilding JP; Daousi C
Diabet Med; 2012 Aug; 29(8):e205-10. PubMed ID: 22486277
[TBL] [Abstract][Full Text] [Related]
8. Improved meal-related insulin processing contributes to the enhancement of B-cell function by the DPP-4 inhibitor vildagliptin in patients with type 2 diabetes.
Ahrén B; Pacini G; Tura A; Foley JE; Schweizer A
Horm Metab Res; 2007 Nov; 39(11):826-9. PubMed ID: 17992639
[TBL] [Abstract][Full Text] [Related]
9. Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on beta-cell function in patients with type 2 diabetes: a model-based approach.
Xu L; Man CD; Charbonnel B; Meninger G; Davies MJ; Williams-Herman D; Cobelli C; Stein PP
Diabetes Obes Metab; 2008 Dec; 10(12):1212-20. PubMed ID: 18476982
[TBL] [Abstract][Full Text] [Related]
10. Effect of metformin on intact proinsulin and des 31,32 proinsulin concentrations in subjects with non-insulin-dependent (type 2) diabetes mellitus.
Nagi DK; Ali VM; Yudkin JS
Diabet Med; 1996 Aug; 13(8):753-7. PubMed ID: 8862952
[TBL] [Abstract][Full Text] [Related]
11. Sitagliptin 100 mg daily effect on DPP-4 inhibition and compound-specific glycemic improvement.
Alba M; Sheng D; Guan Y; Williams-Herman D; Larson P; Sachs JR; Thornberry N; Herman G; Kaufman KD; Goldstein BJ
Curr Med Res Opin; 2009 Oct; 25(10):2507-14. PubMed ID: 19691426
[TBL] [Abstract][Full Text] [Related]
12. DPP-4 inhibitors and GLP-1 analogues: for whom? Which place for incretins in the management of type 2 diabetic patients?
Halimi S
Diabetes Metab; 2008 Feb; 34 Suppl 2():S91-5. PubMed ID: 18640591
[TBL] [Abstract][Full Text] [Related]
13. Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetes.
Herman GA; Bergman A; Yi B; Kipnes M;
Curr Med Res Opin; 2006 Oct; 22(10):1939-47. PubMed ID: 17022853
[TBL] [Abstract][Full Text] [Related]
14. A comparison of mealtime insulin aspart and human insulin in combination with metformin in type 2 diabetes patients.
Pala L; Mannucci E; Dicembrini I; Rotella CM
Diabetes Res Clin Pract; 2007 Oct; 78(1):132-5. PubMed ID: 17445933
[TBL] [Abstract][Full Text] [Related]
15. Non-linear increase in GLP-1 levels in response to DPP-IV inhibition in healthy adult subjects.
Dai H; Gustavson SM; Preston GM; Eskra JD; Calle R; Hirshberg B
Diabetes Obes Metab; 2008 Jun; 10(6):506-13. PubMed ID: 18284437
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic approach of type 2 diabetes mellitus with GLP-1 based therapies.
Penfornis A; Borot S; Raccah D
Diabetes Metab; 2008 Feb; 34 Suppl 2():S78-90. PubMed ID: 18640590
[TBL] [Abstract][Full Text] [Related]
17. Glucagon-like peptide 1 (GLP-1) secretion and plasma dipeptidyl peptidase IV (DPP-IV) activity in morbidly obese patients undergoing biliopancreatic diversion.
Lugari R; Dei Cas A; Ugolotti D; Barilli AL; Camellini C; Ganzerla GC; Luciani A; Salerni B; Mittenperger F; Nodari S; Gnudi A; Zandomeneghi R
Horm Metab Res; 2004 Feb; 36(2):111-5. PubMed ID: 15002062
[TBL] [Abstract][Full Text] [Related]
18. Subcutaneous glucagon-like peptide-1 improves postprandial glycaemic control over a 3-week period in patients with early type 2 diabetes.
Todd JF; Edwards CM; Ghatei MA; Mather HM; Bloom SR
Clin Sci (Lond); 1998 Sep; 95(3):325-9. PubMed ID: 9730852
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the effects of pioglitazone and metformin on hepatic and extra-hepatic insulin action in people with type 2 diabetes.
Basu R; Shah P; Basu A; Norby B; Dicke B; Chandramouli V; Cohen O; Landau BR; Rizza RA
Diabetes; 2008 Jan; 57(1):24-31. PubMed ID: 17914032
[TBL] [Abstract][Full Text] [Related]
20. A Dose-Ranging Study of the DPP-IV Inhibitor PF-734200 Added to Metformin in Subjects With Type 2 Diabetes*.
Terra SG; Somayaji V; Schwartz S; Lewin AJ; Teeter JG; Dai H; Nguyen TT; Calle RA
Exp Clin Endocrinol Diabetes; 2011 Jul; 119(7):401-7. PubMed ID: 21472661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
